VentriPoint Diagnostics Ltd

Company Profile

VentriPoint Diagnostics Ltd had its IPO on under the ticker symbol VPTDF.

The company operates in the Healthcare sector and Medical Devices industry. VentriPoint Diagnostics Ltd has a staff strength of 0 employees.

Stock update

Shares of VentriPoint Diagnostics Ltd opened at $0.15 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.14 - $0.17, and closed at $0.17.

This is a -2.35% slip from the previous day's closing price.

A total volume of 118,710 shares were traded at the close of the day’s session.

In the last one week, shares of VentriPoint Diagnostics Ltd have slipped by -10.42%.

VentriPoint Diagnostics Ltd's Key Ratios

VentriPoint Diagnostics Ltd has a market cap of $26.66 million, indicating a price to book ratio of 8.2705 and a price to sales ratio of 897.0447.

In the last 12-months VentriPoint Diagnostics Ltd’s revenue was $51348 with a gross profit of $-6268 and an EBITDA of $-5038146. The EBITDA ratio measures VentriPoint Diagnostics Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, VentriPoint Diagnostics Ltd’s operating margin was -9827.93% while its return on assets stood at -54.66% with a return of equity of -113.24%.

In Q2, VentriPoint Diagnostics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 84.2%.

VentriPoint Diagnostics Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into VentriPoint Diagnostics Ltd’s profitability.

VentriPoint Diagnostics Ltd stock is trading at a EV to sales ratio of 705.6483 and a EV to EBITDA ratio of -5.8498. Its price to sales ratio in the trailing 12-months stood at 897.0447.

VentriPoint Diagnostics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$3.89 million

Total Liabilities

$1.17 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

VentriPoint Diagnostics Ltd ended 2025 with $3.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $3.89 million while shareholder equity stood at $2.39 million.

VentriPoint Diagnostics Ltd ended 2025 with $0 in deferred long-term liabilities, $1.17 million in other current liabilities, in common stock, $-51081550.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.31 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $82959.00.

VentriPoint Diagnostics Ltd’s total current assets stands at $3.61 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $13686.00 compared to accounts payable of $835173.00 and inventory worth $0.

In 2025, VentriPoint Diagnostics Ltd's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, VentriPoint Diagnostics Ltd paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$0.17

52-Week High

$0.255

52-Week Low

$0.0918

Analyst Target Price

$

VentriPoint Diagnostics Ltd stock is currently trading at $0.17 per share. It touched a 52-week high of $0.255 and a 52-week low of $0.255. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.2 and 200-day moving average was $0.18 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 175% of the company’s stock are held by insiders while 0% are held by institutions.